Search

Author/Creator Keystone, E

12. OP0086 The fully human anti-tnf monoclonal antibody, adalimumab (d2e7), dose ranging study: the 24-week clinical results in patients with active ra on methotrexate therapy (the armada trial). (1st June 2001)

Authors:
Keystone, E; Weinblatt, ME; Weisman, M; Furst, D; Paulus, H; Birbara, C; Fischkoff, S; Chartash, EK
Journal:
Annals of the rheumatic diseases
Issue:
Volume 60(2001)Supplement 1
Page Start:
A481
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

14. OP0203 Impact of adalimumab serum concentration on efficacy and association between ANTI-DRUG antibodies and serum concentration: 24 week results from a phase III study comparing SB5 (an adalimumab biosimilar) with reference adalimumab in patients with rheumatoid arthritis. (15th June 2017)

Authors:
Kay, J; Weinblatt, M; Keystone, E; Genovese, M; Ghil, J; Cheong, SY; Hong, EE
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
136
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

15. OP0204 Impact of anti-drug antibody and injection site reaction on efficacy: 24-week results from a phase iii study comparing SB4 (etanercept biosimilar) with reference etanercept in patients with rheumatoid arthritis. (15th June 2017)

Authors:
Vencovsky, J; Emery, P; Keystone, E; Ghil, J; Cheong, SY; Hong, EE
Journal:
Annals of the rheumatic diseases
Issue:
Volume 76(2017)Supplement 2
Page Start:
137
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

16. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. Issue 6 (1st July 2008)

Authors:
Smolen, J S; Han, C; van der Heijde, D M F M; Emery, P; Bathon, J M; Keystone, E; Maini, R N; Kalden, J R; Aletaha, D; Baker, D; Han, J; Bala, M; St Clair, E W
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 6(2009)
Page Start:
823
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

17. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Issue 10 (12th September 2008)

Authors:
Aletaha, D; Landewe, R; Karonitsch, T; Bathon, J; Boers, M; Bombardier, C; Bombardieri, S; Choi, H; Combe, B; Dougados, M; Emery, P; Gomez-Reino, J; Keystone, E; Koch, G; Kvien, T K; Martin-Mola, E; Matucci-Cerinic, M; Michaud, K; O'Dell, J; Paulus, H
Journal:
Annals of the rheumatic diseases
Issue:
Volume 67:Issue 10(2008)
Page Start:
1360
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

18. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Issue 2 (3rd April 2008)

Authors:
Keystone, E; Emery, P; Peterfy, C G; Tak, P P; Cohen, S; Genovese, M C; Dougados, M; Burmester, G R; Greenwald, M; Kvien, T K; Williams, S; Hagerty, D; Cravets, M W; Shaw, T
Journal:
Annals of the rheumatic diseases
Issue:
Volume 68:Issue 2(2009)
Page Start:
216
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗